From Investing.com: 2024-05-13 12:32:20

will reimburse for DefenCath when administered on an outpatient basis. We continue to progress discussions with major US dialysis providers and have secured a procurement contract with ARC Dialysis. Additionally, we are exploring expansion into new markets like TPN and oncology. Our financial strategy remains strong with a planned breakeven profitability by the end of 2024. Thank you for your continued support and interest in CorMedix.



Read more at Investing.com: CorMedix outlines robust Q1 2024 milestones and financials By Investing.com